RAPID Pharmacovigilance in Palliative Care

RAPID Data Collection
An international, multi-site, consecutive cohort, post-marketing study of the real world net clinical effects of medications and non-pharmacological interventions used in hospice/palliative care – RAPID

Palliative care has sought to improve its evidence base for clinical prescribing. A complementary way of adding to the evidence base includes pharmacovigilance studies (phase IV studies, post marketing data, adverse drug reaction reporting) that provide data on widespread and longer term use of medications or other interventions such as blood transfusions. These studies are cost effective, timely and genuinely add to the knowledge for clinical prescribing and other therapies, by defining the net benefit (clinical response together with toxicity) on data from the target audience, in this case palliative care practices around the world.

The evidence collected from these studies directly informs clinical practice, as well as, pharmaceutical policies around the world.

RAPID Objectives
To prospectively collect information on:
- The therapeutic benefit of medications and interventions commonly used in palliative care;
- The toxicity of medications and interventions commonly used in palliative care; and
- Any significant drug/drug interactions of medications commonly used in palliative care.

Primary outcome measurement/endpoint
- The primary outcome is to evaluate the benefit and toxicity of medications and interventions commonly used in palliative care.
- Secondary outcomes include: to describe the indications for medications and interventions being used in palliative care, and to document the frequency of prescribing of common medications and interventions in palliative care.

The RAPID program has 35 active sites from 16 countries that are participating or have expressed interest in the program. There have been X medication series completed and Y non-pharmacological intervention series complete. All have been, or are in the process of being published.

Evidence from these studies directly inform practice

RAPID Program
The medication series commenced in 2011 with one medication series. The program has now expanded to include a medication series across six symptom areas commonly experienced in palliative care including: pain, breathlessness, gut dysfunction, nausea, mood and cognitive disorders and appetite and cachexia.

A non-pharmacotherapeutic intervention series continues to run concurrently with the medication series.
Further Reading

Rationale for the RAPID study series:


Contact
PaCCSC – Palliative Care Clinical Studies Collaborative

T: +61 (0)2 9514 4862
+61 (0)8 7421 9726
E: rapid@uts.edu.au
W: www.uts.edu.au/paccsc
@ pa_ccsc

UTS CRICOS PROVIDER CODE: 00099F